Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Bulls ‘n Bears interview with Dr Chris Burns
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial
FDA Fast Track Designation Granted to Narmafotinib in Pancreatic Cancer
Investor Newsletter | September 2024
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Fifth partial response confirmed in ACCENT trial
Categories
Archive
Company News
Investor Newsletters
Videos
09 May 2022
ABC News | Bioshares
Read More
19 Apr 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
07 Apr 2022
VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial
Read More
05 Apr 2022
New investment in pancreatic cancer research
Read More
30 Mar 2022
Amplia is hiring
Read More
17 Mar 2022
Scientific rigour is in our DNA
Read More
17 Feb 2022
Improving Pancreatic Cancer Survival Rates
Read More
11 Feb 2022
WOMEN IN SCIENCE | Rhiannon Jones, Director, Operations
Read More
01 Feb 2022
VIDEO | PROACTIVE Amplia Therapeutics readies for phase two clinical trials and "watershed year" for AMP945
Read More
24 Jan 2022
Quarterly Report & 4C
Read More
02 Dec 2021
$2.1M R&D Cash Flow Loan
Read More
30 Nov 2021
VIDEO | SMALL CAPS Amplia Therapeutics makes headway in anti-cancer clinical trial
Read More
18 Nov 2021
VIDEO | PROACTIVE Amplia Therapeutics details summary results from its phase 1 clinical trial of AMP945
Read More
17 Nov 2021
New Phase 1 Clinical Trial Data
Read More
10 Nov 2021
VIDEO | AUSBIZ Amplia's $12M plan; what's next for the Aussie medtech
Read More
10 Nov 2021
VIDEO | Proactive Investors, $12.4m Capital Raise
Read More
08 Nov 2021
$12.4m Capital Raise
Read More
26 Oct 2021
Amplia appoints leading drug developer as Oncology Clinical Advisor
Read More
21 Oct 2021
Switzer Daily | Therapeutics company primed for growth
Read More
07 Oct 2021
MEET THE TEAM | Dr John Lambert, CEO
Read More
1
2
3
4
5
6